With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.169447-70-5,(S)-tert-Butyl 2-methylpiperazine-1-carboxylate,as a common compound, the synthetic route is as follows.
Step 1: Synthesis of (S)-tert-butyl-2-methyl-4-(pyrimidin-2-yl)piperazine-1-carboxylate To the mixture of 2-chloropyrimidine (200 mg, 1.75 mmol), (S)-tert-butyl-2-methylpiperazine-1-carboxylate (350 mg, 1.75 mmol), and DIPEA (677 mg, 5.24 mmol) was added DMF (4 mL). The mixture was stirred at 100 C. for 3 hrs, then extracted with EtOAc/H2O (50 mL/50 mL). The organic phase was dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by chromatography (silica, PE/EtOAc=0-10%) to afford (S)-tert-butyl-2-methyl-4-(pyrimidin-2-yl)-piperazine-1-carboxylate (330 mg, 67.8%). MS (EI+, m/z): 279 [M+H]+., 169447-70-5
As the paragraph descriping shows that 169447-70-5 is playing an increasingly important role.
Reference：
Patent; Navitor Pharmaceuticals, Inc.; O’Neill, David John; Saiah, Eddine; Kang, Seong Woo Anthony; Brearley, Andrew; Bentley, Jonathan; (136 pag.)US2019/389843; (2019); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics